Members Members Residents Job Board
Join Today Renew Your Membership Make A Donation
2006 Abstracts: Radiofrequency ablation for HCC in cirrhotic patients: prognostic factors for survival
Back to 2006 Program and Abstracts
Radiofrequency ablation for HCC in cirrhotic patients: prognostic factors for survival
Andrea Ruzzenente, Marco Sandri, Calogero Iacono, Silvia Pachera, Corrado Pedrazzani, Sebastiano Tasselli, Alfredo Guglielmi; Surgery and Gastroenterology, University of Verona , Verona , Italy

Background: Radiofrequency ablation of hepatocellular carcinoma has proved to be useful in local control of tumor, few data on survival after treatment are available in literature. The aim of the study was to evaluate factors related to survival and to identify different classes of risk after radiofrequency ablation. Methods: ninety-eight cirrhotic patients with 145 hepatocellular carcinomas were treated with radiofrequency ablation from January 1998 to May 2004. In 55 patients cirrhosis was in Child-Pugh class A and in 43 in class B. Tumor was single in 60 and multiple in 38, mean tumor number was 1.5 (range 1-3). Tumor size ranged from 1.5 to 6.0 cm, mean 3.8 cm. Mean follow up period was 24.9 months. Radiofrequency ablation was performed with expandable type needle with percutaneous approach under real-time ultrasound guidance. For statistical analysis univariate and multivariate analysis were performed. Results: Complete ablation of the tumor was achieved in 85.5 % of lesions. 1- and 3- years survival was 76.7 % and 36.6 %, respectively. Univariate analysis showed that CLIP (Cancer of The Liver Italian Program) score, tumor growth pattern, alpha-fetoprotein level and complete tumor necrosis, were factors significantly related to poor survival. Multivariate analysis identified that factors related to poor survival were alpha-fetoprotein level > 100 ng/ml, Child-Pugh class B and incomplete tumor necrosis with an hazard ratio of 4.0, 2.7 and 3.8, respectively. After complete ablation median survival was 38 months in patients with Child-Pugh class A cirrhosis and alpha-fetoprotein level 100 ng/ml, 22 months for patient with Child-Pugh class B cirrhosis and alpha-fetoprotein 100 ng/ml and 9 months for patient with Child-Pugh class A cirrhosis and alpha-fetoprotein > 100 ng/ml (p < 0.01). Conclusions: Complete necrosis and absence of residual tumor positively affect survival after treatment. In patients with Child-Pugh A cirrhosis and alpha-fetoprotein level 100 radiofrequency ablation have results that are comparable to those of surgical resection, 55% after 3 years. In patients with Child-Pugh B cirrhosis and/or alpha-fetoprotein > 100 ng/ml showed less satisfactory results.


Back to 2006 Program and Abstracts


Society for Surgery of the Alimentary Tract

Facebook Twitter YouTube

Email SSAT Email SSAT
500 Cummings Center, Suite 4400, Beverly, MA 01915 500 Cummings Center
Suite 4400
Beverly, MA 01915
+1 978-927-8330 +1 978-927-8330
+1 978-524-0498 +1 978-524-0498
Links
About
Membership
Publications
Newsletters
Annual Meeting
Join SSAT
Job Board
Make a Pledge
Event Calendar
Awards